Anixa Biosciences Inc (ANIX): R&D Expense
$5.07M
Year ended 2025-10-31
$4.83M
Trailing 12 months to 2026-07-31
-8.9%
3-year compound annual growth
+3.0%
5-year compound annual growth
+21.7%
10-year compound annual growth
| Period ended | R&D Expense | Change YoY | Source filing |
|---|---|---|---|
| 2025-10-31 | $5.07M | -20.7% | 2026-01-12, From 2024-11-01 |
| 2024-10-31 | $6.40M | +34.1% | 2026-01-12, From 2023-11-01 |
| 2023-10-31 | $4.77M | -28.9% | 2025-01-10, From 2022-11-01 |
| 2022-10-31 | $6.70M | +8.3% | 2024-01-16, From 2021-11-01 |
| 2021-10-31 | $6.19M | +41.3% | 2023-01-04, From 2020-11-01 |
| 2020-10-31 | $4.38M | -20.0% | 2022-01-04, From 2019-11-01 |
| 2019-10-31 | $5.47M | -19.7% | 2021-01-07, From 2018-11-01 |
| 2018-10-31 | $6.81M | +326.5% | 2020-01-09, From 2017-11-01 |
| 2017-10-31 | $1.60M | +2.6% | 2019-01-11, From 2016-11-01 |
| 2016-10-31 | $1.56M | +118.8% | 2018-01-09, From 2015-11-01 |
| 2015-10-31 | $711.4K | n/a | 2016-12-08, From 2014-11-01 |
| No annual figure between 2012-10-31 and 2015-10-31. | |||
| 2012-10-31 | $2.21M | -29.2% | 2014-01-17, From 2011-11-01 |
| 2011-10-31 | $3.12M | +3.9% | 2013-01-29, From 2010-11-01 |
| 2010-10-31 | $3.01M | n/a | 2012-01-30, From 2009-11-01 |
R&D Expense at similar companies
| Company | Year ended | R&D Expense | Change YoY |
|---|---|---|---|
| Anixa Biosciences Inc (ANIX) | 2025-10-31 | $5.07M | -20.7% |
| Aprea Therapeutics, Inc. (APRE) | 2025-12-31 | $7.04M | -24.8% |
| Reviva Pharmaceuticals Holdings, Inc. (RVPH) | 2025-12-31 | $11.71M | -48.9% |
| Aditxt, Inc. (ADTX) | 2025-12-31 | $3.19M | -70.7% |
| Synlogic, Inc. (SYBX) | 2025-12-31 | $43.0K | -99.5% |
| Tempest Therapeutics, Inc. (TPST) | 2025-12-31 | $12.61M | -55.7% |
| Lipocine Inc. (LPCN) | 2025-12-31 | $8.58M | +16.8% |
| Cingulate Inc. (CING) | 2025-12-31 | $9.77M | +3.5% |
| Cellectar Biosciences, Inc. (CLRB) | 2025-12-31 | $11.50M | -56.0% |
Compare ANIX, APRE, RVPH, ADTX side by side · Screen every company in Pharmaceutical Preparations ↗